We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Tempest Therapeutics (TPST) USD0.001

Sell:$2.00 Buy:$2.31 Change: $0.14 (6.51%)
Market closed |  Prices as at close on 1 July 2022 | Switch to live prices |
Sell:$2.00
Buy:$2.31
Change: $0.14 (6.51%)
Market closed |  Prices as at close on 1 July 2022 | Switch to live prices |
Sell:$2.00
Buy:$2.31
Change: $0.14 (6.51%)
Market closed |  Prices as at close on 1 July 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Tempest Therapeutics, Inc. (Tempest) is a clinical-stage oncology company. The Company is focused on developing therapeutics that combine both targeted and immune-mediated mechanisms to treat a wide range of tumors. The Company’s two clinical programs include TPST-1495 and TPST-1120. TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor. TPST-1120 is in Phase I and II trials in solid tumors, including a global randomized Phase Ib/II trial in combination with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). TPST-1495, is a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is in a Phase I monotherapy and combination trial in solid tumors.

Contact details

Address:
7000 SHORELINE COURT, SUITE 275
SOUTH SAN FRANCISCO
94080
United States
Telephone:
+1 (415) 7988589
Website:
https://www.tempesttx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
TPST
ISIN:
US87978U1088
Market cap:
$22.61 million
Shares in issue:
10.32 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Thomas Dubensky
    President, Director
  • Stephen Brady
    Chief Executive Officer, Director
  • Samuel Whiting
    Executive Vice President, Chief Medical Officer
  • Nicholas Maestas
    Vice President - Strategy and Finance

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.